Blog
RSS FeedPosted by Michael Wonder on 22 Mar 2021
Early benefit assessment - the whole spectrum
19 March 2021 - IQWiG evaluated a total of 24 manufacturer dossiers punctually for the dates March 1 and March 15. ...
Posted by Michael Wonder on 01 Mar 2021
Nusinersen in spinal muscular atrophy: indication of considerable added benefit in children with an early onset of the disease
1 March 2021 - The treatment delays permanent ventilation of the children and extends life. In addition, the children develop more ...
Posted by Michael Wonder on 01 Mar 2021
Dapagliflozin in chronic heart failure: hint of added benefit
1 March 2021 - Diabetes drug is also effective in symptomatic chronic heart failure with reduced pump function. However, the additional ...
Posted by Michael Wonder on 22 Feb 2021
Clinical relevance of patient-reported outcomes: new threshold proves to be practical
18 February 2021 - Current examples show that the 15% threshold newly set by IQWiG for the recognition of responder analyses ...
Posted by Michael Wonder on 22 Feb 2021
Germans turn backs on AstraZeneca vaccine
22 February 2021 - Germany’s vaccination program is in trouble, with people failing to keep appointments if they are going ...
Posted by Michael Wonder on 04 Jan 2021
Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR
4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are ...
Posted by Michael Wonder on 03 Dec 2020
Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment
3 December 2020 - Inappropriate treatment in the control arm makes fair comparison impossible. ...
Posted by Michael Wonder on 02 Dec 2020
IQWiG publishes 1,000th report
2 December 2020 - In the 16th year of its existence, IQWiG has published its 1,000th report: a dossier assessment ...
Posted by Michael Wonder on 19 Nov 2020
Trifarotene in moderate acne: no study data for the assessment of the added benefit
16 November 2020 - Only studies with placebo comparisons despite many affected people and existing treatment alternatives. ...
Posted by Michael Wonder on 05 Nov 2020
IQWiG publishes a new version of its general methods
5 November 2020 - New features include the investigation of volume-outcome relationships and different mean observation times in clinical studies. ...
Posted by Michael Wonder on 01 Oct 2020
Fostamatinib in chronic immune thrombocytopenia: added benefit not proven due to lack of comparison
1 October 2020 - Only placebo controlled studies in the dossier. ...
Posted by Michael Wonder on 29 Sep 2020
Germany has not fully realised its biosimilar potential
29 September 2020 - Investigators have concluded that fully realizing the cost-saving potential of biosimilars could “release enormous resources” for ...
Posted by Michael Wonder on 21 Sep 2020
Second joint meeting on ‘Innovations in Healthcare’
18 September 2020 - How can methodological and scientific advice to manufacturers of medicinal products be further optimised at European level ...
Posted by Michael Wonder on 17 Sep 2020
The best possible security of supply for cancer therapy with CAR-T cells
17 September 2020 - Medical facilities that treat patients with novel cell therapies (CAR-T cells) must meet newly defined quality requirements. ...
Posted by Michael Wonder on 02 Sep 2020
Talazoparib in breast cancer: hint of considerable added benefit
1 September 2020 - Advantages in health related quality of life, symptoms and side effects outweigh disadvantages. ...